The Prospect and Challenges of Repurposing Established Drugs in Pulmonary Arterial Hypertension
BioChem · 10.09.2024 · 4 (3) · 236-251
DOI: 10.3390/biochem4030012 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioChem, online erschienen am 10.09.2024. Verfasst von Sila Ozlem Sener und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GrowMedtech, Commonwealth Scholarship Commission (CSC), Great Britain Sasakawa Foundation.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a progressive disorder caused by the narrowing of small blood vessels in the lungs, which, in the absence of therapies, leads to right heart failure and premature death. No cure for this devastating disorder is known. Current management therapies aim to improve symptoms, and hence, there is a need to identify novel therapeutic interventions. The major objectives of this review are to critically evaluate current treatment strategies and highlight the challenges and prospects of established drugs and natural products for the resolution of PAH.
Förderung
- GrowMedtech
- Commonwealth Scholarship Commission (CSC)
- Great Britain Sasakawa Foundation
- University of Bradford (UoB)
- TUBITAK
Zitieren
APA
Sener, S. O., Nasim, R., & Nasim, T. (2024). The Prospect and Challenges of Repurposing Established Drugs in Pulmonary Arterial Hypertension. BioChem, 4(3), 236-251. https://doi.org/10.3390/biochem4030012
Vancouver
Sener SO, Nasim R, Nasim T. The Prospect and Challenges of Repurposing Established Drugs in Pulmonary Arterial Hypertension. BioChem. 2024;4(3):236-251. doi:10.3390/biochem4030012
BibTeX
@article{Sener2024,
author = {Sener, Sila Ozlem and Nasim, Rateep and Nasim, Talat},
title = {The Prospect and Challenges of Repurposing Established Drugs in Pulmonary Arterial Hypertension},
journal = {BioChem},
year = {2024},
volume = {4},
number = {3},
pages = {236--251},
doi = {10.3390/biochem4030012}
}
EUVIMED